Related Experiment Videos
Combination therapy with interferon-alpha and ribavirin for hepatitis C: practical treatment issues
1Department of Gastroenterology, John Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9DU, England. Jane.collier@orh.nhs.uk
Summary
Combination therapy with ribavirin and interferon-alpha (IFN-alpha) treats chronic hepatitis C, achieving a 40% sustained response rate. Future treatments may involve more effective pegylated interferons for improved outcomes.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Chronic hepatitis C infection is commonly treated with a 6- to 12-month combination therapy of ribavirin and interferon-alpha (IFN-alpha).
- The current standard treatment yields an overall sustained response rate of 40%.
- Treatment indications include detectable hepatitis C virus (HCV) RNA, elevated transaminases, and liver fibrosis or inflammation.
Purpose of the Study:
- To review the current treatment standards for chronic hepatitis C.
- To discuss the efficacy and adverse effects of ribavirin and IFN-alpha combination therapy.
- To explore potential future treatment advancements, including pegylated interferons.
Main Methods:
- Review of current clinical guidelines and research on hepatitis C treatment.
- Analysis of sustained response rates based on HCV genotype and viral load.
- Evaluation of common adverse events associated with ribavirin and IFN-alpha therapy.
Main Results:
- The sustained response rate for current combination therapy is 40%, with lower rates observed in genotype 1 and high viral loads.
- Anemia (due to ribavirin) and neuropsychiatric effects (due to IFN-alpha) are the most common adverse events, leading to treatment cessation in 10-20% of patients.
- Standard IFN-alpha is administered subcutaneously three times weekly.
Conclusions:
- Ribavirin and IFN-alpha combination therapy is the current standard but has limitations in efficacy and tolerability.
- Pegylated interferons, offering once-weekly administration and potentially greater effectiveness, are likely to replace standard IFN-alpha in future treatment regimens.
- Further research into optimizing treatment duration, dosage, and novel therapeutic agents is warranted to improve sustained response rates and patient outcomes.